Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 1Q

Foreign exchange and Consumer Care divestiture impact results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck

1Q Revenues: $9.4 billion (-8%)

1Q Earnings: $953 million (-44%)

Comments: Pharmaceutical sales were $8.3 billion, down 2% in the quarter. JANUVIA/JANUMET sales were $1.4 billion, up 4%. ZETIA/VYTORIN sales were down 9% to $887 million. REMICADE sales were down 17% to $501 million. ISENTRESS sales were $385 million, down 1%. GARDASIL / GARDASIL 9 sales were down 6% to $359 million. PROQUAD, M-M-R II and VARIVAX sales were up 24% to $348 million. Animal Health revenues were up 2% to $829 million. Results include a 5% negative impact from foreign exchange and a 9% unfavorable impact from the divestiture of the Consumer Care business and select products, partially offset by the acquisition of Cubist Pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters